DMPK Consultancy
Strategic DMPK input is essential to maximize success across the drug discovery pipeline. At Sygnature Discovery, our expert DMPK consultancy services span from hit identification through to candidate nomination, offering scientific guidance at every stage of the drug discovery process. Through integrated ADME and pharmacokinetic support, independent reviews and tailored advice, we help researchers anticipate challenges, refine strategies and drive candidates towards clinical success.
Comprehensive DMPK Support Across Discovery Stages
At Sygnature Discovery, our DMPK consultancy provides early and continuous input into drug discovery programs. We specialize in embedding DMPK strategy into Hit Identification, Hit-to-Lead, and Lead Optimisation stages, particularly for challenging areas such as CNS drug discovery, and new emerging fields such as heterobifunctional degraders and ADCs.
Drawing on extensive experience, our scientists help shape compound selection, refine screening cascades, and guide progression based on bioavailability, exposure, and metabolic profiles. Our consultancy approach ensures that potential ADME and PK liabilities are identified early, allowing for proactive solutions that improve the likelihood of downstream success.
Independent Review and Expert Problem-Solving
Beyond program integration, Sygnature Discovery offers independent DMPK consultancy reviews to support critical project milestones. Our team provides detailed, unbiased critiques of discovery-stage projects, identifying risks and proposing data-driven strategies for progression.
We also offer comprehensive reviews of research proposals, ensuring that DMPK considerations are incorporated effectively before experimental work begins. Where challenges arise, our scientists bring practical problem-solving expertise, offering tailored solutions to overcome ADME and pharmacokinetic hurdles.
DMPK Due Diligence for Licensing and Investment
Our DMPK consultancy services also support strategic decision-making for in-licensing, out-licensing, and investment evaluations. Through third-party due diligence assessments, we critically review DMPK packages, highlighting strengths, weaknesses, and potential risks.
By combining scientific rigour with commercial awareness, we help clients make confident decisions about compound viability, whether entering partnerships, pursuing acquisitions, or preparing assets for market.
Why Choose Sygnature Discovery for DMPK Consultancy?
Sygnature Discovery’s DMPK team brings deep cross-sector expertise, having advanced 56 drug candidates into clinical development across big pharma, biotech, CROs, and academia. Our DMPK consultancy is grounded in:
- Extensive expertise across multiple discovery programs and therapeutic areas
- Strong integration of ADME and PK strategy from early-stage discovery onward
- Objective, solutions-focused assessments to guide project success
- Flexible support models – standalone consultancy or integrated collaboration
We act as true partners in discovery, delivering expert advice, critical analysis and translational insights to strengthen your discovery pipeline.